Send to

Choose Destination
Curr Top Med Chem. 2019;19(1):74-97. doi: 10.2174/1568026619666190125144621.

Peptide Sequence-Dominated Enzyme-Responsive Nanoplatform for Anticancer Drug Delivery.

Author information

First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, 030001, China.
Institute of Medical Engineering, Department of Biophysics, School of Basic Medical Science, Health Science Center, Xi'an Jiaotong University, No.76 Yanta West Road, Xi'an, Shaanxi 710061, China.
School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.


Enzymatic dysregulation in tumor and intracellular microenvironments has made this property a tremendously promising responsive element for efficient diagnostics, carrier targeting, and drug release. When combined with nanotechnology, enzyme-responsive drug delivery systems (DDSs) have achieved substantial advancements. In the first part of this tutorial review, changes in tumor and intracellular microenvironmental factors, particularly the enzymatic index, are described. Subsequently, the peptide sequences of various enzyme-triggered nanomaterials are summarized for their uses in various drug delivery applications. Then, some other enzyme responsive nanostructures are discussed. Finally, the future opportunities and challenges are discussed. In brief, this review can provide inspiration and impetus for exploiting more promising internal enzyme stimuli-responsive nanoDDSs for targeted tumor diagnosis and treatment.


DDSs; Enzyme-responsive; Peptide; Sequence; Targeted drug delivery; Tumor microenvironment.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Bentham Science Publishers Ltd.
Loading ...
Support Center